Guggenheim Capital’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-46,517
| Closed | -$54.9K | – | 1641 |
|
|
2025
Q1 | $54.9K | Sell |
46,517
-7,943
| -15% | -$9.37K | ﹤0.01% | 1623 |
|
|
2024
Q4 | $99.7K | Sell |
54,460
-17,703
| -25% | -$32.4K | ﹤0.01% | 1653 |
|
|
2024
Q3 | $123K | Sell |
72,163
-117,661
| -62% | -$200K | ﹤0.01% | 1816 |
|
|
2024
Q2 | $260K | Sell |
189,824
-37,702
| -17% | -$51.7K | ﹤0.01% | 1687 |
|
|
2024
Q1 | $853K | Buy |
227,526
+32,149
| +16% | +$121K | 0.01% | 1260 |
|
|
2023
Q4 | $1.92M | Buy |
195,377
+43,021
| +28% | +$422K | 0.01% | 861 |
|
|
2023
Q3 | $1.27M | Sell |
152,356
-75,735
| -33% | -$632K | 0.01% | 991 |
|
|
2023
Q2 | $3.03M | Sell |
228,091
-35,293
| -13% | -$469K | 0.02% | 693 |
|
|
2023
Q1 | $3.05M | Sell |
263,384
-17,912
| -6% | -$207K | 0.03% | 704 |
|
|
2022
Q4 | $2.3M | Sell |
281,296
-35,551
| -11% | -$291K | 0.02% | 802 |
|
|
2022
Q3 | $1.84M | Sell |
316,847
-7,529
| -2% | -$43.7K | 0.02% | 872 |
|
|
2022
Q2 | $1.43M | Sell |
324,376
-125,732
| -28% | -$555K | 0.01% | 1049 |
|
|
2022
Q1 | $4.1M | Buy |
450,108
+31,330
| +7% | +$285K | 0.02% | 724 |
|
|
2021
Q4 | $8.57M | Buy |
418,778
+81,136
| +24% | +$1.66M | 0.04% | 486 |
|
|
2021
Q3 | $8.63M | Buy |
337,642
+331,309
| +5,231% | +$8.46M | 0.05% | 436 |
|
|
2021
Q2 | $221K | Buy |
+6,333
| New | +$221K | ﹤0.01% | 2112 |
|
|
2019
Q4 | – | Sell |
-14,080
| Closed | -$73K | – | 2138 |
|
|
2019
Q3 | $73K | Sell |
14,080
-17,943
| -56% | -$93K | ﹤0.01% | 2074 |
|
|
2019
Q2 | $194K | Buy |
32,023
+127
| +0.4% | +$769 | ﹤0.01% | 2037 |
|
|
2019
Q1 | $231K | Buy |
+31,896
| New | +$231K | ﹤0.01% | 2013 |
|